Yeast Biosurfactants Trigger Severe Stress and Cell Death in Breast Cancer Models

Yeast-derived biosurfactants can dismantle human breast cancer cells in laboratory tests by triggering severe cellular stress and membrane disruption, according to a recent study. Researchers investigated how a mixture of natural glycolipids impacts MCF-7 breast adenocarcinoma cells, revealing a potent cytotoxic effect that halts cell growth and damages vital internal structures.

How Biosurfactants Target Breast Cancer Cells

Breast cancer remains the most frequently diagnosed malignant neoplasm among women worldwide, accounting for roughly 2.3 million new cases and 670,000 deaths annually. While modern treatments continue to advance, persistent medical challenges and regional health disparities drive the search for safer, more effective therapeutic alternatives derived from natural sources.

In this laboratory investigation published in 3 Biotech, a research team led by scientists from the State University of Londrina in Brazil examined the precise mechanisms by which microbial glycolipids affect cancerous cells. The team tested a compound mixture containing 63.15% lactonic forms and 36.85% acidic forms, which are secondary metabolites produced by the non-pathogenic yeast Starmerella bombicola.

What Happens When Cancer Cells Meet Yeast Glycolipids

When exposed to these microbial molecules for 24 hours, human breast cancer cells experienced a dose-dependent reduction in cell viability. The half-maximal inhibitory concentration, representing the dose required to reduce cell viability by 50 percent, was measured at 82.54 micrograms per milliliter. Phase-contrast microscopy and fluorescence staining revealed severe morphological alterations, including cell swelling, loss of adhesion, and compromised plasma membrane integrity.

Flow cytometry analysis further showed that the treatment caused cells to arrest in the S phase of the cell cycle, preventing normal division. Additionally, researchers observed significant mitochondrial membrane depolarization, indicating that the powerhouses of the cells were failing under metabolic strain.

Unraveling the Molecular Stress Pathways

At the transcriptional level, reverse transcription quantitative PCR demonstrated the overexpression of several key stress-response genes, including CDKN1A, GADD45A, ERN1, and BBC3. The upregulation of ERN1 points to endoplasmic reticulum stress, a state where cellular protein folding machinery becomes overwhelmed. Meanwhile, the increase in BBC3 activity promotes mitochondrial membrane permeability, compounding the cellular damage.

Interestingly, while the intrinsic apoptotic pathway was engaged, the cells predominantly underwent necrosis-like cell death, reaching 59.31 percent at the highest concentration tested. The authors note that the MCF-7 cell line naturally lacks functional caspase-3 due to a genetic deletion, which prevents the completion of classical programmed cell death. Instead, the amphiphilic nature of the glycolipids causes direct physical damage to the cell membrane, accompanied by the downregulation of structural and metabolic genes such as ACTB and GAPDH.

Next Steps for Natural Antiproliferative Therapies

These findings position microbial biosurfactants as promising candidates for the development of alternative antiproliferative therapies. However, the study authors emphasize several important limitations that must be addressed in future research. The experiments were conducted exclusively on a single in vitro cell line with specific genetic traits, and the use of an unseparated mixture of lactonic and acidic isoforms makes it impossible to isolate the exact contribution of each structural form.

Subsequent investigations will need to evaluate isolated fractions individually, incorporate non-malignant control lines, and extend the testing into complex in vivo models. These steps are necessary to fully understand the safety, efficacy, and clinical potential of these yeast-derived compounds before they can be considered for medical applications.

The research was published in 3 Biotech on November 1, 2026.